U.S. markets closed

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
60.32+4.08 (+7.25%)
At close: 4:00PM EDT
Sign in to post a message.
  • g
    geminidealer
    They best get the share price up otherwise Carl will be bought out with a lowball price
  • R
    Ryan
    Road to 300 is long but it will come. Great products, great company, great leadership.
    Bullish
  • d
    daniel
    They need to get more diagnosis’s and volume in order to get these share prices up👍🏽
  • d
    daniel
    People need to buy more into this stock
    Bullish
  • P
    Paul
    Why down today or just market action?
  • Y
    Yahoo Finance Insights
    Castle Biosciences is down 9.70% to 56.22
  • r
    reality check entertainment
    Through December 31, 2020, DecisionDx-Melanoma has been ordered more than 68,920 times for use in patients with cutaneous melanoma. $cstl
    Bullish
  • r
    reality check entertainment
    Earnings good , company should be at$ 100
    Bullish
  • T
    Tony
    How can I buy in
  • S
    S
    CSTL Longs:

    Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions
  • A
    Alan
    Nice earnings report
    Bullish
  • r
    reality check entertainment
    When is quiet period over ?
    Bullish
  • Y
    Yahoo Finance Insights
    Castle Biosciences is up 10.59% to 68.76
  • S
    S
    This will be back in no time. Just reacting to the market.
    Bullish
  • M
    MCL
    Disappointed with the latest earnings and management expects next couple of quarters to be weak. Think the stock will lose momentum for a while
    Bearish
  • M
    MCL
    Think it will go down to high 40s
  • Y
    Yahoo Finance Insights
    Castle Biosciences is down 10.21% to 61.30
  • Y
    Yahoo Finance Insights
    Castle Biosciences is down 9.23% to 67.39
  • A
    Anonymous
    I have personal experience with the application of this test in patients with melanoma since 2018. The results are only getting more accurate and informative as they add new genetic sequences they find to be associated with more aggressive tumors.
    Right now, if insurance won’t pay, CSTL bears the cost. They’re so confident in the data sets they are building, and they should be. These tests will be the gold standard in many areas of cancer treatment, skin and otherwise.
    Bullish
  • L
    Longboat
    This company looks interesting!